Recent News

• 09.28.2025 - Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
• 09.24.2025 - Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
• 09.09.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference
• 09.09.2025 - Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
• 08.29.2025 - Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
• 08.27.2025 - Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
• 08.26.2025 - Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

Recent Filings

• 09.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.19.2025 - 144 Report of proposed sale of securities
• 09.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2025 - 144 Report of proposed sale of securities
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities